Anticoagulant therapy likely increases risk of bleeding in Gynura segetum-induced hepatic sinus obstruction syndrome

Youwen Tan,Xingbei Zhou
DOI: https://doi.org/10.1097/md.0000000000035914
IF: 1.6
2024-02-10
Medicine
Abstract:Hepatic sinusoidal obstruction syndrome (HSOS) is characterized by edema, necrosis, and abscission of endothelial cells in the hepatic sinusoids, hepatic venules, and interlobular veins resulting in microthrombosis, intrahepatic congestion, functional liver injury, and acute portal hypertension. Tusanqi has become the main cause of HSOS in China because it contains pyrrolidine alkaloids (PAs) that can damage hepatic sinusoidal endothelial cells and cause HSOS. [ 1–3 ] There is currently no specific treatment for HSOS. Once the clinical diagnosis is made, Chinese herbal medicines containing PAs should be discontinued. Routine treatments, such as supportive measures, diuresis, and management aimed at improving microcirculation, may effectively improve the prognosis of mild HSOS. Among patients who respond poorly to medical treatment, anticoagulants are an effective treatment option. Some researchers have reported the use of unfractionated or low-molecular-weight heparin for the treatment of Tusanqi-induced HSOS with success rates of 70% to 88.9%. [ 4–7 ] Anticoagulant therapy is associated with serious complications such as bleeding, which renders its use controversial. Therefore, here we retrospectively analyzed the clinical characteristics of 49 patients with Tusanqi-induced HSOS as well as the benefits and risks associated with anticoagulant therapy.
medicine, general & internal
What problem does this paper attempt to address?